Zhejiang Orient Gene Biotech Co Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunologic… Read more
Market Cap & Net Worth: Zhejiang Orient Gene Biotech Co Ltd (688298)
Zhejiang Orient Gene Biotech Co Ltd (SHG:688298) has a market capitalization of $636.90 Million (CN¥4.67 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #12870 globally and #3241 in its home market, demonstrating a 1.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Orient Gene Biotech Co Ltd's stock price CN¥23.18 by its total outstanding shares 201600000 (201.60 Million).
Zhejiang Orient Gene Biotech Co Ltd Market Cap History: 2020 to 2026
Zhejiang Orient Gene Biotech Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $2.94 Billion to $636.90 Million (-17.82% CAGR).
Zhejiang Orient Gene Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Orient Gene Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.97x
Zhejiang Orient Gene Biotech Co Ltd's market cap is 0.97 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.94 Billion | $3.27 Billion | $1.68 Billion | 0.90x | 1.75x |
| 2021 | $3.41 Billion | $10.17 Billion | $4.92 Billion | 0.34x | 0.69x |
| 2022 | $1.67 Billion | $8.77 Billion | $2.07 Billion | 0.19x | 0.81x |
| 2023 | $982.55 Million | $820.16 Million | -$397.58 Million | 1.20x | N/A |
| 2024 | $805.88 Million | $827.92 Million | -$529.02 Million | 0.97x | N/A |
Competitor Companies of 688298 by Market Capitalization
Companies near Zhejiang Orient Gene Biotech Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Zhejiang Orient Gene Biotech Co Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Zhejiang Orient Gene Biotech Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Zhejiang Orient Gene Biotech Co Ltd's market cap moved from $2.94 Billion to $ 636.90 Million, with a yearly change of -17.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥636.90 Million | -1.07% |
| 2025 | CN¥643.77 Million | -20.12% |
| 2024 | CN¥805.88 Million | -17.98% |
| 2023 | CN¥982.55 Million | -41.26% |
| 2022 | CN¥1.67 Billion | -50.91% |
| 2021 | CN¥3.41 Billion | +15.94% |
| 2020 | CN¥2.94 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Zhejiang Orient Gene Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $636.90 Million USD |
| MoneyControl | $636.90 Million USD |
| MarketWatch | $636.90 Million USD |
| marketcap.company | $636.90 Million USD |
| Reuters | $636.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.